SHR 1314

Drug Profile

SHR 1314

Alternative Names: SHR-1314

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atridia; Jiangsu Hengrui Medicine Co.
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis
  • Preclinical Autoimmune disorders

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Psoriasis (In volunteers) in Australia (SC) (NCT02934412)
  • 01 Jul 2016 Jiangsu Hengrui Medicine plans a phase I trial for Autoimmune diseases in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top